Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Transfusion Medicine Reviews

• Publication date

  1998-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0887-7963(98)80002-3PMID 9798269
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discrepancies between meta-analyses and subsequent large randomized, controlled trials.

  1997cited by this paper
• Evidence‐based medicine: the case for white cell reduction

  1997cited by this paper
• Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

  1997cited by this paper
• Meta‐analysis in transfusion medicine

  1997cited by this paper
• A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection.

  1997cited by this paper
• Algorithm for managing the platelet refractory patient

  1997cited by this paper
• Language bias in randomised controlled trials published in English and German.

  1997cited by this paper
• Principles of counting low numbers of leukocytes in leukoreduced blood components.

  1997cited by this paper
• The promise and problems of meta-analysis.

  1997cited by this paper
• The perils of platelet transfusions.

  1997cited by this paper
• A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet‐B light in patients with hematologic malignancy

  1996cited by this paper
• Lessons learned from decision analysis

  1996cited by this paper
• Platelet transfusion therapy.

  1996cited by this paper
• A critical perspective on the tools to support clinical decision making

  1996cited by this paper
• Principles of transfusion medicine

  1996cited by this paper
• Large trials vs meta-analysis of smaller trials: how do their results compare?

  1996cited by this paper
• Predictive ability of meta-analyses of randomised controlled trials.

  1995cited by this paper
• The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions.

  1995cited by this paper
• A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.

  1995cited by this paper
• Meta-analysis: statistical alchemy for the 21st century.

  1995cited by this paper
• Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?

  1995cited by this paper
• The practice of meta-analysis.

  1995cited by this paper
• The Handbook of Research Synthesis

  1995cited by this paper
• Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.

  1995cited by this paper
• Immunology of transfusion medicine : edited by G. Garratty, Marcel Dekker, 1994, $195.00 (xi + 712 pages) ISBN 00 8247 9122 3

  1995cited by this paper
• Biologic effects of leukocytes present in transfused cellular blood products.

  1994cited by this paper
• Canadian Red Cross Society symposium on leukodepletion: report of proceedings.

  1994cited by this paper
• Random effects models.

  1994cited by this paper
• HLA Antigens on Leukocyte Fragments and Plasma Proteins: Prestorage Leukoreduction by Filtration

  1994cited by this paper
• Prevention of HLA alloimmunization by using leukocyte-depleted components.

  1994cited by this paper
• Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated

  1994cited by this paper
• Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group

  1994cited by this paper
• Biologic effects of leukocytes present in transfused cellular blood products

  1994cited by this paper
• The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies.

  1994cited by this paper
• Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group.

  1994cited by this paper
• Large-scale randomized evidence: large, simple trials and overviews of trials.

  1993cited by this paper
• Cost‐effectiveness of white cell‐reduction filters in treatment of adult acute myelogenous leukemia

  1993cited by this paper
• Blood Transfusion and Immunomodulation: A Possible Mechanism

  1993cited by this paper
• Large‐Scale Randomized Evidence: Large, Simple Trials and Overviews of Trials

  1993cited by this paper
• Can We Learn Anything from Small Trials?

  1993cited by this paper
• Doing more good than harm : the evaluation of health care interventions

  1993cited by this paper
• Leukocyte Depletion of Red Cell Concentrates by Filtration: Influence of Blood Product Temperature

  1992cited by this paper
• [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusions: a prospective multi-institutional study using a polyester platelet filter].

  1992cited by this paper
• Prevention of alloimmunization against platelets.

  1991cited by this paper
• Prevention of alloimmunization in patients with acute leukemia by use of white cell‐reduced blood components—a randomized trial

  1991cited by this paper
• Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.

  1991cited by this paper
• Have you ever meta-analysis you didn't like?

  1991cited by this paper
• Prevention of platelet alloimmunization

  1991cited by this paper
• Theoretic and practical aspects of platelet crossmatching.

  1990cited by this paper
• Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components.

  1990cited by this paper
• Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components

  1990cited by this paper
• The challenge of platelet alloimmunization: management and prevention.

  1990cited by this paper
• Meta-analysis in medicine. Where we are and where we want to go.

  1989cited by this paper
• Meta-analysis: science or religion?

  1989cited by this paper
• Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion.

  1989cited by this paper
• Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.

  1988cited by this paper
• Clinical factors influencing the efficacy of pooled platelet transfusions

  1988cited by this paper
• Alloimmunization after Leukocyte‐Depleted Multiple Random Donor Platelet Transfusions

  1988cited by this paper
• Clinical factors influencing the efficacy of pooled platelet transfusions.

  1988cited by this paper
• Prevention of refractoriness and HLA-alloimmunization using filtered blood products.

  1988cited by this paper
• Statistical Methods for Meta-Analysis

  1987cited by this paper
• Methods for combining randomized clinical trials: strengths and limitations.

  1987cited by this paper
• Meta-analysis in clinical research.

  1987cited by this paper
• Prevention of platelet alloimmunization.

  1986cited by this paper
• Use of leucocyte‐poor blood components and HLA‐matched‐platelet donors to prevent HLA alloimmunization

  1986cited by this paper
• Prevention of platelet alloimmunization.

  1986cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Transfusion medicine, recent technological advances.

  1986cited by this paper
• A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia.

  1983cited by this paper
• Fundamentals of Clinical Trials

  1982cited by this paper
• ANTIGENIC SPECIFICITY OF ANTIBODY REACTIVE IN THE ANTIGLOBULIN‐AUGMENTED LYMPHOCYTOTOXICITY TEST

  1982cited by this paper
• Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.

  1981cited by this paper
• Etude technique immunologique et clinique des performances de filtration du sang à l'aide de l'appareil Erypur

  1981cited by this paper
• Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.

  1981cited by this paper
• [Technical, immunological and clinical study of the performance of blood filtration using Erypur filters].

  1981cited by this paper
• Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing.

  1969cited by this paper

• [Selection of blood products to reduce immunization before HLA-mismatched allogeneic transplantation (SFGM-TC)].

  2025cites this paper
• Immunological consequences of past transfusions in kidney transplant candidates: A focus on anti-HLA antibody formation

  2025cites this paper
• Insights into platelet post-transfusional human leukocyte antigen I immunization.

  2025cites this paper
• Evaluation of influence of IL-6 C-572G gene polymorphism and clinical factors on positive platelet antibody test

  2021cites this paper
• Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.

  2020cites this paper
• Improving blood transfusion safety in resource-poor countries: a case study of using leucocyte reduced blood in Uganda

  2020cites this paper
• Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice

  2019cites this paper
• Platelet transfusion: Current challenges.

  2018cites this paper
• Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2017cites this paper
• Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.

  2017cites this paper
• Immunological complications of blood transfusions.

  2016cites this paper
• Leucoreduction of blood components: an effective way to increase blood safety?

  2016cites this paper
• Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.

  2015cites this paper
• Antibody‐mediated transfusion‐related acute lung injury; from discovery to prevention

  2015influential citation
• Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).

  2015cites this paper
• Approach to managing platelet refractory patients

  2015cites this paper
• Release of cytokines in stored whole blood and red cell concentrate: Effect of leukoreduction

  2015cites this paper
• UvA-DARE ( Digital Academic Repository ) Coagulopathy and plasma transfusion in critically ill patients

  2014cites this paper
• Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.

  2013cites this paper
• Chapter 41 – Leukoreduction of Blood Products

  2013cites this paper
• Cytofluorimetric Platelet Analysis

  2013cites this paper
• Detection of presensitization in recipients of kidney transplants

  2013cites this paper
• Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?

  2013cites this paper
• Transfusion of Blood and Blood Products

  2012cites this paper
• Prevention of immune-mediated transfusion-related acute lung injury; from bloodbank to patient.

  2012cites this paper
• Transfusion-related acute lung injury: a preventable syndrome?

  2012cites this paper
• Appropriate blood component usage

  2011cites this paper
• Clinical effects of leucoreduction of blood transfusions.

  2011cites this paper
• Dermatomyositis and polymyositis: new treatment targets on the horizon.

  2011cites this paper
• From whole blood to component therapy: The economic, supply/demand need for implementation of component therapy in sub-Saharan Africa Du sang total aux médicaments dérivés du sang : nécessité économique de l'utilisation des dérivés du sang en Afrique sub-saharienne

  2011cites this paper
• Reduktion der Inzidenz von antierythrozytären Alloantikörpern durch die Leukozytendepletion von Erythrozytenkonzentraten

  2011cites this paper
• From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.

  2011cites this paper
• Impact of Photodynamic Treatment with Meso‐substituted Porphyrin on the Immunomodulatory Capacity of White Blood Cell‐containing Red Blood Cell Products

  2010cites this paper
• Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors

  2010cites this paper
• Pathogen inactivation in cellular blood products by photodynamic treatment

  2010cites this paper
• Clinical Evaluation of Alloantibodies in Solid Organ Transplantation

  2009cites this paper
• Leukoreduction of Blood Products

  2009cites this paper
• Why implement universal leukoreduction?

  2008cites this paper
• Chapter 26 – Leukocyte-Reduced Products

  2007cites this paper
• Red Blood Cell Alloimmunization after Blood Transfusion

  2007cites this paper
• Management of patients refractory to platelet transfusion.

  2007cites this paper
• Evidence-based platelet transfusion guidelines.

  2007cites this paper
• The clinical benefits of the leukoreduction of blood products.

  2006cites this paper
• The case against universal white blood cell reduction

  2006cites this paper
• Platelet transfusion therapy: from 1973 to 2005.

  2006cites this paper
• Balancing evidence and public opinion in health technology assessments: The case of leukoreduction

  2006cites this paper
• Blood Transfusion as Regulator of the Immune Response

  2006cites this paper
• Blood Transfusion as Regulator of the Immune Response

  2006cites this paper
• Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study

  2005cites this paper
• Landmark studies that have changed the practice of transfusion medicine

  2005cites this paper
• Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.

  2004cites this paper
• Flow Cytometry in Transfusion Medicine: Development, Strategies and Applications

  2004cites this paper
• Chapter 7 – Leukoreduced Products: Prevention of Leukocyte-Related Transfusion-Associated Adverse Effects

  2004cites this paper
• LEUCOREDUCTION UNE MESURE ENVISAGEABLE DANS LE CADRE DE LA POLITIQUE NATIONALE DE SECURITE DES

  2004cites this paper
• What has universal leucodepletion given us: evidence from clinical trials?

  2004cites this paper
• What has universal leucodepletion given us: evidence from clinical trials?

  2004cites this paper
• Essential Role of OX40L on B Cells in Persistent Alloantibody Production Following Repeated Alloimmunizations

  2004cites this paper
• Management of Patients Refractory to Platelet Transfusion

  2003cites this paper
• Prophylactic platelet transfusions: which dose is the best dose? A review of the literature.

  2003cites this paper
• Applications of Meta‐Analysis in Transfusion Medicine

  2003cites this paper
• HLA and RBC immunization after filtered and buffy coat‐depleted blood transfusion in cardiac surgery: a randomized controlled trial

  2003cites this paper
• Signs and symptoms associated with the transfusion of WBC‐reduced RBCs and non‐WBC‐reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study

  2002cites this paper
• The pediatrician and medical care of the child with cancer.

  2002cites this paper
• Immunological aspects of blood transfusions.

  2002cites this paper
• A novel true volumetric method for the determination of residual leucocytes in blood components

  2002cites this paper
• Status Report on the Quality of Liquid and Frozen Red Blood Cells

  2002cites this paper
• Thrombocytopenia and Critical Care Medicine

  2001cites this paper
• Immunomodulation: Facts and Interpretations

  2001cites this paper
• Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cites this paper
• Applications of meta-analysis in pathology practice.

  2001cites this paper
• Blood transfusion: Quo vadis? Customer orientation as the leading principle for blood banks in the future

  2001cites this paper
• Universal leucocyte‐depletion of blood components: cell concentrates and plasma

  2001cites this paper
• Universal WBC reduction:the case for and against

  2001cites this paper
• Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.

  2001cites this paper
• Contributions of Meta-Analysis to Transfusion Medicine

  2001cites this paper
• Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro.

  2000cites this paper
• Clinical Significance of Leukoreduktion of Blood Components

  2000cites this paper
• Immunological aspects of blood transfusions.

  2000cites this paper
• Does General Leukocyte Depletion Provide Any Better Clinical Outcome

  1999cites this paper
• Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients.

  1999cites this paper